Entacapone, a novel calechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

European Journal of Pharmacology

Volumn 340, Issue 2-3, 1997, Pages 287-294

  Nissinen, Erkki ^a   Kaheinen, Petri ^a   Penttilä, Kai E ^a   Kaivola, Juha ^a   Lindén, Inge Britt ^a  

^a ORION CORPORATION   (Finland)

Author keywords

Catechol O methyltransferase; Entacapone; Mitochondria; Oxidative phosphorylation; Uncoupling

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; TOLCAPONE; ADENINE NUCLEOTIDE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; ENZYME INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PARKINSON DISEASE; PRIORITY JOURNAL; T CELL LYMPHOMA; ANIMAL; CELL RESPIRATION; DRUG ANTAGONISM; DRUG EFFECT; GUINEA PIG; HEART; IN VITRO STUDY; KINETICS; LEUKEMIA L 1210; METABOLISM; MOUSE; RAT; WISTAR RAT;

ADENINE NUCLEOTIDES; ANIMALS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CELL RESPIRATION; ENERGY METABOLISM; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HEART; KINETICS; LEUKEMIA L1210; MALE; MICE; MITOCHONDRIA, LIVER; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RATS; RATS, WISTAR;

EID: 0031565076     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01431-3     Document Type: Article

References (36)

1. Ahtila S., Kaakkola S., Gordin A., Korpela K., Heinävaara S., Karlsson M., Wikberg T., Tuomainen P., Männistö P.T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol. 18:1995;46-57.
2. Bindoff L.A., Birch-Machin M., Cartlidge N.E.F., Parker W.D. Jr., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet. 1:1989;49.
3. Brown G.C. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem. J. 284:1992;1-13.
4. Carter A.J., Müller R.E. Application and validation of an ion-exchange high-performance liquid chromatographic method for measuring adenine nucleotides, creatine and creatine phosphate in mouse brain. J. Chromatogr. 527:1990;31-39.
5. Cleeter M.J.W., Cooper J.M., Schaphira A.H.V. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
6. +) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137:1986;310-315.
7. Dingmanse J., Jorga K., Zürcher G., Schmitt M., Sedek G., Da Prada M., Van Brummelen P. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Pharmacol. 40:1995;253-262.
8. Hatefi Y. Mitochondrial electron transport and oxidative phosphorylation system. Ann. Rev. Biochem. 54:1985;1015-1069.
9. Hemker H.C. Lipid solubility as a factor influencing the activity of uncoupling phenols. Biochim. Biophys. Acta. 62:1962;46-54.
10. Hemker H.C. Inhibition of adenosine diphosphatase and respiration of rat liver mitochondria by dinitrophenols. Biochim. Biophys. Acta. 81:1964;1-8.
11. Jackson-Lewis V., Naini A.B., Przedborski S., Simonetti S., Fahn S., Cadet J.L. Catecholamines inhibit mitochondrial complex I activity in rat brain. Soc. Neurosci. Abstr. 17:1991;1276.
12. Keränen T., Gordin A., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Schultz E., Seppälä E., Wikberg T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 46:1994;151-157.
13. 31P NMR measurement of mitochondrial uncoupling in isolated rat hearts J. Biol. Chem. 265:1990;1545-1550.
14. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
15. Leidtke A.J., DeMaison L., Eggleston A.M., Cohen L., Nellis S.H. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ. Res. 62:1988;535-542.
16. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schaphira A.H.V., Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain. 115:1992;333-342.
17. Martín M.A., Molina J.A., Jiménez-Jiménez F.J., Benito-León J., Ortí-Pareja M., Campos Y., Arenas J. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Neurology. 46:1996;1343-1346.
18. Merello M., Lees A.J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;186-189.
19. Miller J.W., Selhub J., Joseph J.A. Oxidative damage caused by free radicals produced during catecholamine autooxidation: Protective effects of O-methylation and melatonin. Free Radiat. Biol. Med. 21:1996;241-249.
20. Mingatto F.E., Santos A.C., Uyemura S.A., Jordani M.C., Curti C. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: Respiration and ATP synthesis. Arch. Biochem. Biophys. 334:1996;303-308.
21. Mizuno Y., Suzuki K., Sone N., Saitoh T. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci. Lett. 91:1988;349-353.
22. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163:1989;1450-1455.
23. Männistö P.T., Tuomainen P. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: Modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;412-418.
24. Nissinen E., Lindén I.-B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;262-266.
25. Opie, L.H., 1991. ATP synthesis and breakdown; adenosine and response to ischemia. In: Opie, L. (Ed.), The Heart, Physiology and Metabolism. Raven Press, New York, NY, pp. 247-276.
26. Opie L.H., Bricknell O.L. Role of glycolytic flux and the effect of glucose in decreasing fatty acid induced release of lactate dehydrogenase from isolated coronary ligated rat heart. Cardiovasc. Res. 13:1979;693-702.
27. 2+ in toxic cell killing. Trends Pharmacol. Sci. 10:1989;281-285.
28. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
29. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreira M., Naini A.B., Fahn S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34:1993;715-723.
30. Schaphira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1:1989;1269.
31. Schaphira A.H.V., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (Complex I) deficiency in Parkinson's disease. J. Neurochem. 55:1990;2142-2145.
32. Somasundaram S., Hayllar H., Rafi S., Wrigglesworth J.M., Macpherson A.J.S., Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: A review and a hypothesis. Scand. J. Gastroenterol. 30:1995;289-299.
33. Spencer C.M., Benfield P. Tolcapone: New drug profile. CNS Drugs. 5:1996;475-481.
34. Stryer, L., 1981. Oxidative phosphorylation. In: Stryer, L. (Ed.), Biochemistry. W.H. Freeman and Company, New York, NY, pp. 307-331.
35. Terada H. The interaction of highly active uncouplers with mitochondria. Biochem. Biophys. Acta. 639:1981;225-242.
36. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural. Transm. 4:1992;27-34.